Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®
Aug 28, 2013
Aradigm's Proprietary Inhaled Antibiotic for the Chronic Therapy of Patients with Severe Respiratory Disease is Advancing Into Phase III BARCELONA, Spain & HAYWARD, Calif. --(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB)
Aradigm Announces Second Quarter 2013 Financial Results
Aug 08, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2013 . Total revenue was approximately $0.2 million for both the second quarter of 2013 and the second quarter of 2012.
Aradigm Awarded NIH Grant to Investigate New Methods of Diagnoses of Aspirations of Gastrointestinal Contents into the Respiratory Tract with Scientists at UC San Francisco
Aug 07, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Heart, Lung, and Blood Institute , National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Pulmaquin and Lipoquin
Aug 01, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), awarded Aradigm Corporation (OTCBB:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of pulmonary non-tuberculous
Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin
Jul 16, 2013
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced that the Company's shareholders approved all
Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
May 21, 2013
Aradigm's Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease BARCELONA, Spain & HAYWARD, Calif. --(BUSINESS WIRE)-- Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm")
Aradigm Announces First Quarter 2013 Financial Results
May 14, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2013 . Total revenue was $0.3 million for the first quarter of 2013, compared with $0.3 million in revenue for the first
Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results
Mar 26, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2012 . Fourth Quarter 2012 Results The Company recorded $223,000 in revenue in the fourth quarter of 2012 compared with
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12
Feb 06, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 15 th Annual BIO CEO & Investor Conference 2013 on Tuesday, February 12, 2013 , at 2:00 p.m. ET .
Aradigm to Present at Biotech Showcase 2013 on January 9
Jan 03, 2013
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2013 on Wednesday, January 9, 2013 , at 11: 00 a.m. Pacific time.
Aradigm Announces Private Placement for $6 Million
Dec 12, 2012
Proceeds Will Further Development of Inhaled Ciprofloxacin for the Treatment of Severe Respiratory Diseases HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it has entered into a definitive agreement for the sale of common stock to two
UK Scientists Report on Efficacy of Aradigm's Lipoquin™ Against Pneumonic Plague
Nov 19, 2012
A Single Dose of Aradigm's Liposomal Ciprofloxacin Delivered 24 Hours Post-Exposure with a Lethal Dose of Plague Provided Full Protection HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have
Aradigm Announces Third Quarter 2012 Financial Results
Nov 08, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2012 . Total revenue was approximately $0.3 million for the third quarter of 2012 compared with revenue of
Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
Oct 16, 2012
Major Inflammation Stimulating Factor Produced During Serious Lung Infections Inhibited by Aradigm's Drug HAYWARD, Calif. --(BUSINESS WIRE)-- Today at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Chicago, IL , scientists from the Virginia Commonwealth
UK Scientists Report Successful Testing of Aradigm's Inhaled Liposomal Ciprofloxacin in Q Fever
Sep 20, 2012
Q Fever is a Highly Infectious and Life Threatening Infection HAYWARD, Calif. --(BUSINESS WIRE)-- UK scientists from the Health Protection Agency (HPA) and Defence Science and Technology Laboratory (Dstl) reported this week at the University of Southampton's Wessex Life Sciences Alliance Conference
New U.S. Composition of Matter Patent for Aradigm's Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
Sep 18, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) (" Aradigm " or the "Company") today announced that the United States Patent and Trademark Office has issued an important new composition of matter patent (U.S. Patent No. 8,268,347) to Aradigm for formulations of liposomal and
Aradigm Patent Protection for Smoking Cessation is Extended with Issuance of a Method of Treatment Patent
Sep 05, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB: ARDM) ("Aradigm" or the "Company") today announced that the United States Patent and Trademark Office has issued an important method of treatment patent (U.S. Patent No. 8,256,433) covering Systems and Methods for Effecting Cessation
Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
Aug 30, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Igor Gonda , PhD., Aradigm's President and CEO, will be a panel member at the U.S. Food and Drug Administration's public workshop regarding the design of clinical trials of antibacterial drugs
Aradigm to Present at the Stifel Nicolaus 2012 Healthcare Conference
Aug 29, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota , Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons
Aradigm Announces Second Quarter 2012 Financial Results
Aug 09, 2012
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2012 . Total revenue was approximately $0.2 million for both the second quarter of 2012 and the second quarter of 2011.
Displaying 81 - 100 of 240
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2019 Aradigm Corporation. All Rights Reserved.